Qing-Re-Qu-Shi Formula, Eczema and the Gut Microbiome: Reading a Multi-Omics Trial

Evidence interpretation, not individualized diagnosis or prescribing.

What the trial investigated

A randomized placebo-controlled study evaluated the Qing-Re-Qu-Shi herbal formula in adults with moderate atopic dermatitis. Investigators combined clinical outcomes with gut-microbiome and circulating-metabolite analyses to explore possible gut–skin mechanisms.

Why multi-omics data can mislead

Sequencing and metabolomics measure thousands of features. Without prespecified pathways and correction for multiple comparisons, chance associations are likely. A microbe or metabolite that changes with symptom improvement may be a marker rather than a mediator. Diet, antibiotics and baseline geography can strongly shape results.

Herbal does not mean standardized or risk-free

Complex formulas can vary by plant species, cultivation, extraction, dose and contamination controls. They may interact with anticoagulants, immunosuppressants, liver-metabolized medicines or pregnancy. Findings for one standardized research product cannot be transferred to teas, supplements or similarly named products sold online.

Clinical evidence comes first

The relevant questions are whether validated eczema scores, itch, sleep and quality of life improved compared with placebo, how missing data were handled and whether adverse events were fully reported. Mechanistic results should support—not replace—the randomized clinical comparison.

Safety boundaries

Do not give an adult herbal formula to a baby or child. Pregnant or breastfeeding people and those with liver, kidney or bleeding disorders should consult qualified clinicians before any botanical supplement. Report jaundice, dark urine, severe abdominal pain or allergic symptoms promptly.

Bottom line

The study is a sophisticated formula-specific experiment. Replication, chemical standardization and longer safety follow-up are required before broad recommendations.

Related Dr. Arsy evidence reviews

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Qing-Re-Qu-Shi multi-omics randomized trial
2. Systemic therapies and skin bacteriome pilot
3. Abrocitinib and the skin microbiome study
4. Oral microbiome with dupilumab or upadacitinib
5. Topical Lactobacillus lactis pilot trial
6. Washed microbiota transplantation study
7. Nature-based microbial exposure pilot
8. Child dupilumab skin and gut microbiome pilot
9. Pediatric skin-microbiome emollient trial
10. Pediatric gut and skin microbiota case-control study
11. XZ.700 endolysin randomized trial
12. Staphylococcus hominis A9 safety trial
13. B244 itch randomized trial
14. Farnesol moisturizer microbiome study
15. AAD topical therapy guideline
16. AAD systemic therapy guideline
17. AAAAI/ACAAI GRADE guideline
18. Atopic dermatitis microbiome review
19. Staphylococcus aureus and atopic dermatitis review
20. Skin microbiome in atopic dermatitis review
21. Dupilumab SOLO phase 3 trials
22. Upadacitinib Measure Up trials
23. Abrocitinib JADE MONO-1 trial
24. HOME core outcome set

Cited publications do not endorse #003.